Table 1.

Summarizes the clinical and laboratory profile of all the cases.

	Case 1	Case 2	Case 3	Case 4	Case 5	Case 6	Case 7	Case 8	Case 9	Case 10	Case 11
age	36 years	29 years	60 years	56 years	58 years	27 years	21 years	17 years	35 years	49 years	58 years
Sex	Male	Male	Male	Female	Male	Male	Male	Female	Male	Female	Female
Hematological disease	B-cell ALL	B-cell ALLIsolated CNS Relapsed	Multiple myeloma	Multiple myeloma	Multiple myeloma	cHL	CML with T cell lymphoid blast crisis	B cell ALL	AML	AML	DLBCL
Stem cell Transplant type	Allo HCT	Allo HCT	Auto /Allo HCT	Auto HCT	Auto HCT	Auto HCT	Allo HCT	Allo HCT	Allo HCT	Allo HCT	Auto HCT
Time from HCT to COVID-19 symptoms	10.7 month (+323days)	5.6 month (+170 day)	192 month	71 month	53 month	9.1 month(+275days)	day +5	13.8month (+415 days)	14 month (421 days)	6.8 month (+206 days)	2 month (+60 days)
Prophylactic antimicrobials	Acyclovir, Bactrim	Acyclovir, Bactrim	Acyclovir, Bactrim	Acyclovir, Bactrim	Acyclovir, Bactrim	Acyclovir, Bactrim	Acyclovir	Acyclovir	Acyclovir posaconazole	Acyclovirbactrim	Acyclovir Bactrim fluconazole
Immunosuppressant	non	tacrolimus	Dexamethasone	non	Dexamethasone Revlimid	Brentuximab	CSA,MMF	Dasatinib	predinosolone 15mg	non	non
Disease status	remission	Relapsed	Relapsed	remission	remission	remission	Unknown	remission	remission	remission	remission
COVID-19 Symptoms	fever and fatigue	fever, runny nose, headache and cough	Fever, headache, fatigue and body aches	headache, fatigability and SOB	Sore throat, fever and runny nose	Loss of smell	asymptomatic	asymptomatic	generalized fatigue, fever and productive cough	Cough, SOBSore throat andChest pain	Fever, SOB
comorbidity	no	aGVHD skin	GVHD gut	DM,HTN,AF	morbid obesity, Hypothyroidism	no	no	no	DM	no	DM,HTN,CKD Hypothyroidism
COVID-19 stage	mild	moderate	mild	moderate	mild	mild	moderate	mild	moderate	moderate	moderate
Hospital admission	no	yes	yes	yes	no	no	no	no	yes	yes	yes
Mechanical ventilation required	no	no	no	no	no	no	no	no	no	no	no
COVID-19 treatment	Symptomatic treatment	Azithromycin, HCQ,Ceftriaxone	non	Ceftriaxone	symptomatic management	non	Azithromycin, HCQ meropenum	non	Azithromycin, HCQ, Ceftriaxone	symptomatic management	Azithromycin, HCQ meropenum
Oxygen therapy required	no	no	no	no	no	no	no	no	no	no	no
Chest X ary finding	Not indicated	ground-glass opacity in the left lower lung zone	Not indicated	opacity in right lower zone	Not indicated	Not indicated	multifocal patchy ground-glass opacities in left lung	Not indicated	bilateral patchy ground glass opacities	Not indicated	left lower lobe ground-glass opacities
WBCs (3.9–11.0) 10^9/L	NA	4.04	NA	2.86	NA	NA	0.07	6.8	4.69	NA	3.2
lymphocyte (1.5–4.3) 10^9/L	NA	2.47	NA	0.8	NA	NA	NA	3.1	1.25	NA	1.85
Neutrophils(30.0–70.0) 10^9/L	NA	1.36	NA	2.1	NA	NA	NA	3.0	2.4	NA	2./3
COVID-19 PCR follow up	negative70 days after confirming the infection	negative 33 days after confirming the infection	negative 86 days after confirming the infection	negative 81 days after confirming the infection	negative 91 days after confirming the infection	not done	positive 42 days after confirming the infection	negative 34 days after confirming the infection	negative 48 days after confirming the infection	not done	negative 65 days after confirming the infection
SARS-Cov2 Total Antibody Screening	Reactiv 70 days after confirming the infection	Reactiv 33 days after confirming the infection	Reactive 86 days after confirming the infection	Reactiv 81 days after confirming the infection	Reactiv 91 days after confirming the infection	not done	Non Reactive 42 days after confirming the infection	not done	Non Reactive 48 days after confirming the infection	not done	Not done

DM-diabetes mellitus, HTN-hypertension, CSA-cyclosporine, ALL-acute lymphoblastic leukemia, auto-autologous, HCT-hematopoietic cell transplant, AF-atrial-fibrillation, MM-Multiple myeloma, SOB-shortness of breath, GVHD-graft versus host disease, HGB-hemoglobin, NA-not available.